Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX-0061

NCT02518620 is registered in ClinicalTrials.gov with Ablynx, a Sanofi company as lead sponsor.

NCT NCT02518620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02518620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX-0061
Lead sponsor
Ablynx, a Sanofi company
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
August 31, 2018
Enrollment
406 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis